BioForce Issued U.S. Patent for NanoArrayer Technology
Dr. Curtis Mosher, Vice President of Research and Development at BioForce and one of the co-authors of this patent stated "In general terms this patent covers a method used to create ultraminiaturized molecular domains on chips. The process described in the patent creates bioanalytical tests that require very small amounts of sample. These tests could be extremely useful in the search for new drugs, and in minimally invasive evaluation of a person's health. Moreover, this method creates the opportunity for rapid screening of many hundreds of molecular species on a single chip requiring less than one drop of blood."
“Method and apparatus for solid state molecular analysis”
Dr. Eric Henderson, Founder and CEO of BioForce Nanosciences, is the primary author of this patent. Dr. Henderson was quoted saying "This patent nicely rounds out a key portion of our intellectual property portfolio. One of the four pillars of the Company is our ability to follow through with innovative concepts from initial invention to commercialization. A technology development company like BioForce depends upon a strong patent portfolio to underpin its ability to successfully introduce and protect its products in the marketplace. We are pleased to see this patent issue and will continue to pursue additional patents as we build our business and establish ourselves as the practical nanotechnology company."
About BioForce Nanosciences, Inc.
BioForce Nanosciences provides innovative and practical commercial products for applications in nanotechnology, with more than a decade of invention, research and development of patented and patent-pending products. The core technology is the NanoArrayer(TM) system, a proprietary platform for precision printing and surface patterning. The NanoArrayer(TM) system includes a consumable line of print cartridges and chip surfaces. This system enables new and important applications in the biomedical and life sciences markets. BioForce continues to target inventions that further expand the reach of its proprietary technology. The ViriChip(TM) System, a patented diagnostic device for rapid detection and identification of multiple viruses on a single chip, is an example of the Company's technology expansion program.
BioForce Nanosciences, the Practical Nanotechnology(TM) company brings inventions to the marketplace as stand-alone products that complement existing innovations, licensing and acquisitions. BioForce is a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH.OB). For more information, visit www.bioforcenano.com or contact BioForce at email@example.com or 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in the company's most recent filings with the Securities and Exchange Commission. The company's actual results could differ materially from such forward-looking statements. We assume no duty to update these statements at any future date.